



[Research article]

RP-HPLC Method Development and Validation for the Simultaneous Estimation of Etodolac and Paracetamol in Tablet Dosage Form

Tabassum*, K.Pranitha, J.Priya, N.Ramathilagam.

Department of Pharmaceutical Analysis and Quality Assurance, Smt.Sarojini Ramulamma College of Pharmacy, Sheshadrinagar, Mahabubnagar - 509001, Andhrapradesh, India

ABSTRACT

A simple reversed-phase high-performance liquid chromatographic (RP-HPLC) method has been developed and validated for simultaneous determination of Etodolac and Paracetamol in pharmaceutical tablet dosage form. Chromatographic analysis was performed on a Symmetry X-terra C8 (4.6mm x 150mm, 5 μ m) column at ambient temperature with a mixture of mixed ortho phosphoric acid buffer and Acetonitrile in the ratio 50:50 v/v OPA buffer; as mobile phase, at a flow rate of 0.9 mL min⁻¹. UV detection was performed at 260 nm. The method was validated for accuracy, precision, linearity and sensitivity. The retention times of Etodolac and Paracetamol were 2.190 and 3.373 min, respectively. Calibration plots were linear over the concentration ranges 4–20 μ g mL⁻¹ and 5–25 μ g mL⁻¹ for Etodolac and Paracetamol, respectively. The Limit of detection was 0.361 and 0.559 μ g mL⁻¹ and the quantification limit were 1.203 μ g mL⁻¹ and 1.864 μ g mL⁻¹ for Etodolac and Paracetamol, respectively. The accuracy of the proposed method was determined by recovery studies and found to be 99.23% to 99.93%. Commercial tablet formulation was successfully analyzed using the developed method and the proposed method is applicable to routine analysis of determination of Etodolac and Paracetamol in pharmaceutical tablet dosage form.

KEYWORDS: Etodolac, Paracetamol, RP-HPLC, Validation.

INTRODUCTION

Paracetamol {N-(4-hydroxyphenyl) acetamide} is analgesic and antipyretic. Etodolac {(RS)-2-(1, 8-Diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl) acetic acid} is an NSAID. Paracetamol is thought to act primarily by increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1 and COX-2, enzymes involved in prostaglandin (PG) synthesis. Unlike NSAIDs, it does not inhibit

cyclooxygenase in peripheral tissues and, thus, has no peripheral anti-inflammatory effects whereas Etodolac inhibits the biosynthesis of prostaglandins by selectively inhibiting COX-2 enzyme, resulting in lower concentrations of prostaglandins. As a consequence, inflammation, pain and fever are reduced. Analytical method for Paracetamol is official in IP, BP and USP and Etodolac is official in BP and USP.

* Corresponding author: Tabassum.
E-mail address: tabassum.tabbu10@gmail.com




Fig 1: Structure of Paracetamol




Fig 2: Structure of Etodolac

MATERIALS AND METHODS

Chemicals/ Reagents and Solvents

Etodolac -300mg and Paracetamol-425mg (ETOVA-P) tablet were obtained from, IPCA Laboratories. Ltd. Mumbai. Double Distilled Water (HPLC grade), Methanol (HPLC grade), Acetonitrile (HPLC grade), orthophosphoric acid and Potassium-dihydrogen phosphate were of reagent grade. The pharmaceutical preparations of combination of Etodolac and paracetamol that is ETOVA-P tablet (IPCA Laboratories. Ltd. Mumbai).

Instrumentation and Equipments

The HPLC analysis was accomplished on WATERS high pressure liquid chromatograph outfitted with 515 reciprocating dual column HPLC pump, a manually operating Rheodyne injector with 20 μ L sample loop, X-terra C₈ 4.6mm x 150mm analytical column reversed-phase material

of 5 μ size and a 2487 model UV-Visible detector. All the parameters of HPLC were controlled by N 2000 chromatographic system software. Other instruments used were TECHCOMP UV-Vis spectrophotometer of model 2310, Shimadzu electronic balance of model XEX-200, ADWA of model AD102U digital pH meter and ENERTECH of model SE60US ultrasonic bath sonicator.

ANALYTICAL METHOD DEVELOPMENT

Optimization of UV conditions

A X-terra symmetry C₈ (4.6mm x 150mm, 5 μ m) was used for chromatographic separation. The mobile phase composed of pH3 Buffer (Orthophosphoric acid): Acetonitrile (50 : 50) at flow rate 0.9 mL/min with run time 6mins. Mobile phase and sample solution were filtered through a 0.45 μ m membrane filter and degassed. The detection of both drugs was carried out at 260nm.




Figure-1. Isobestic point of Etodolac and Paracetamol.

Optimized Method Parameters

Mobile Phase : Phosphate buffer (3.0 pH): Acetonitrile(50:50)
 Column (Stationary Phase): X-terra (C₈) (4.6mm x 150mm, 5 μ m)
 Flow rate (ml/min): 0.9
 Column temperature (°C): Ambient
 Volume of injection loop (μ L): 20
 Detection wavelength (nm): 260
 Drug RT (min): Etodolac- 2.1, Paracetamol- 3.3




Figure 1.1. Optimized chromatogram

PROCEDURE FOR PREPARATION OF SOLUTION

Preparation of buffer

Take 1000ml of HPLC grade water. Dissolve 2.72 grams of Potassium di hydrogen phosphate salt and Adjusted the pH to 3.0 with orthophosphoric acid.

Preparation of mobile phase

A mixture of above prepared buffer 500 ml (50%), and 100 ml of HPLC grade Acetonitrile (50%) were mixed and degassed in ultrasonic water bath for 5 minutes. The mobile phase was filtered through 0.45 µ filter under vacuum.

Diluent Preparation

Use Mobile phase Diluent Phase

ASSAY

Preparation of the Etodolac and Paracetamol standard & sample solution

Preparation of Standard Solution

Accurately weighed and transferred 10 mg of Etodolac and 12.5 mg of Paracetamol working standard into a 10ml clean dry volumetric flask and added about 7.0ml of diluent. It was sonicated to dissolve completely and made volume up to the mark with the same diluent. (Stock solution) From this, 5 ml of the solution was pipette into another 50ml volumetric flask and diluted up to the mark with diluent

From this, 2.4 ml of the solution was pipetted into another 20 ml volumetric flask and diluted up to the mark with diluent.

Sample Solution Preparation

Accurately weighed and transferred tablet powder equivalent to 8 mg of Etodolac and 10 mg of Paracetamol working standard into a 100 ml clean dry volumetric flask and added about 70ml of diluent. It was sonicated to dissolve completely and made volume up to the mark with the same diluent. (Stock solution) From this, 3 ml of the solution was pipetted into another 10ml volumetric flask and diluted up to the mark with diluent..

Procedure

20 µL of the standard and sample solutions were injected into the chromatographic system and areas for the Etodolac and Paracetamol peaks were

measured. %Assay was calculated by using the formula.

Calculation

Assay % =

$$\frac{AT \quad WS \quad DT \quad P \quad \text{Avg. Wt}}{\text{-----} \times \text{-----} \times \text{-----} \times \text{-----} \times \text{-----}} \times 100$$

$$AS \quad DS \quad WT \quad 100 \quad \text{Label Claim}$$

Label Claim

Where:

AT = Average area counts of sample preparation.

AS = Average area counts of standard preparation.

WS = Weight of working standard taken in mg.

P = Percentage purity of working standard

LC = LABEL CLAIM mg/ml.

ANALYTICAL METHOD VALIDATION

The HPLC method was validated in accordance with ICH guidelines.

Accuracy

Accuracy was carried out by % recovery studies at three different concentration levels. To the pre-analyzed sample solution of ETO and PARA a known amount of standard drug powder of ETO and PARA were added at 50, 100 and 150 % level.

Precision

The system precision of the method was verified by five replicate injections of standard solution containing ETO and PARA. The method precision was carried out the analyte five times using the proposed method. Repeatability was measured by multiple injections of a homogenous sample of ETO and PARA.

Linearity

The linearity was determined separately for ETO and PARA. Linearity of the method was studied by injecting 5 concentrations of both drugs prepared in methanol and calibration curves were constructed by plotting peak area against the respective concentrations.

Limit of detection and Limit of quantitation

Sensitivity of the proposed method was estimated in terms of Limit of Detection (LOD) and Limit of Quantitation (LOQ). LOD = 3.3 x ASD/S and LOQ

= $10 \times \text{ASD}/S$, Where, 'ASD' is the average standard deviation and 'S' is the slope of the line.

Robustness

Robustness was evaluated by making deliberate variations in few method parameters such as variation of wave length; flow rate and change in mobile phase composition. The robustness of the method was studied for ETO and PARA.

RESULTS

Selection of Chromatographic Conditions and Optimization of Mobile Phase:

Mobile phase was optimized to separate ETO and PARA using Symmetry C8 column (150 mm x 4.6 mm i.d., 5 μ m). Initially, ACN and phosphate buffer

in the Equal proportions were tried as mobile phase but the splitting of the peaks for both these drugs was observed. Therefore, after adjustment of pH of mixed phosphate buffer to 3.0 with ortho-phosphoric acid, and mobile phase composition (ACN and phosphate buffer in 50:50 % v/v) was tried for resolution of both drugs. Good resolution and symmetric peaks were obtained for both drugs when the pH of the mobile phase (buffer) was adjusted to 3.0. The flow rate of the mobile phase was 0.9 mL min⁻¹. Under optimum chromatographic conditions, the retention time for ETO and PARA was found to be 2.1 and 3.3 min, respectively when the detection was carried out at 260 nm. A typical chromatogram of two drugs is shown in (Figure 1).

Table-1: ACCURACY DATA

Drugs	Amount Added (mg)	Amount Found (mg)	% Recovery	% of mean recovery
Etodolac	12.0	5.28	99.5 %	
	18.0	10.0	100.25 %	99.25 %
	30.0	14.9	98.00 %	
Paracetamol	22.5	5.12	100.00 %	
	30.0	10.0	100.00 %	100.00%
	37.5	15.0	100.00 %	

Table2: SYSTEM PRECISION

S.NO	RT	ETODOLAC		PARACETAMOL	
		AREA	RT	AREA	RT
1	2.098	1931909	3.373	667961	
2	2.090	1885618	3.348	669145	
3	2.090	1853618	3.365	653218	
4	2.082	1857934	3.340	647193	
5	2.098	1864418	3.373	642990	
Average	2.0916	1878699	3.3598	656101.4	
Standard Deviation	0.0066993	32184.49	0.015057	11941.19	
% RSD	0.31999	1.713126	0.45627	1.82	

Table3: METHOD PRECISION

S.NO	ETODOLAC		PARACETAMOL	
	RT	AREA	RT	AREA
1	2.115	1786036	3.39	681699
2	2.09	1828867	3.348	685004
3	2.09	1848587	3.357	691862
4	2.098	1783285	3.373	687733
5	2.115	1816632	3.382	685330
Average	2.1016	1812681.4	3.37	686325.6
Standard Deviation	0.012661	28021.94976	0.017364	3767.485
RSD	0.602	1.545883891	0.51525	0.55

Table 4: Linearity results of Etodolac and Paracetamol

ETODOLAC		PARACETAMOL	
Conc(mcg/ml)	Mean Area	Conc(mcg/ml)	Mean Area
4 ppm	8902478	5 ppm	293111
8 ppm	1453191	10 ppm	506467
12 ppm	1916632	15 ppm	685330
16 ppm	2378262	20 ppm	863014
20 ppm	2936554	25 ppm	1085942

Fig 2: LINEARITY GRAPHS OF ETODOLAC AND PARACETAMOL





Table 5: LOD AND LOQ RESULTS

S.No	Drug name	Standard deviation	Slope	LOD	LOQ
1	Etodolac	14864	123512	0.361034	1.203446
2	Paracetamol	7244	38844	0.559469	1.864895

Table 6 Robustness Result For Etodolac And Paracetamol At Different Condition

S.No	Parameter	Etodolac		Resolution	Paracetamol		
		Theoretical plates per column	Tailing factor		Theoretical plates per column	Tailing factor	Resolution
1	Less flow(0.8ml/min)	2244	1.144	-	4308	1.081	5.6
2	More flow(0.98 ml/min)	1952	1.222	-	3859	1.104	5.3
3	%10 Less organic	2261	1.167	-	4204	1.077	5.6
4	%10 More organic	1965	1.236	-	3653	1.114	5.263

RESULTS AND DISCUSSION

Accuracy

The accuracy of the method studied at three different concentration levels i.e. 50 %, 100 % and 150 % showed acceptable % recoveries in the range of 99.25% % for ETO and 100 % for PARA. The results are shown in Table 1.

Precision

The precision study was evaluated on the basis of % RSD value was found to be in the range 0.3 – 1.82 and 0.5 – 1.5 %, respectively. As the RSD values were < 2% therefore developed method was precise. Results of precision study are shown in Table 2 & 3.

Linearity

The linearity was determined separately for ETO and PARA. Linearity of the method was studied by injecting 5 concentrations of both drugs prepared in methanol and calibration curves were constructed by plotting peak area against the respective concentrations. The ETO and PARA followed linearity in the concentration range of 4– 20 µg

mL-1 and 5-25µg mL-1; respectively. The results are shown in Table 4.and Fig no 2.

Limit of detection and Limit of quantitation

The LOD for ETO and PARA was found to be 0.361034 and 1.203446µg, respectively. The LOQ for ETO and PARA was found to be 0.559469 and 1.864895 µg, respectively. The low values of LOD and LOQ indicates high sensitivity of the method. The results are shown in Table 5.

Robustness study

Robustness of the method was studied by making deliberate changes in the chromatographic conditions and the effects on the results were examined. The low value changes of theoretical plates, tailing factor indicating robustness of the method. When the method was performed by two different analysts under the same experimental and environmental conditions it was found to be rugged and % RSD (less than 2 %) indicating ruggedness of the method. The results are shown in Table 6.

Analysis of marketed tablet formulation

3 replicates of the samples solutions (20 μ L) were injected for quantitative analysis. The amounts of ETO and PARA estimated were found to 99.09 % and 98.42 %, respectively. A good separation and resolution of both drugs indicates that there was no interference from the excipients commonly present

in pharmaceutical formulations. The results are shown in Table 7.

System Suitability Test

The system suitability parameters such as resolution, number of theoretical plates and tailing factor were studied and were summarized in Table 8.

Table 7: ASSAY RESULTS

Assay Results Drug	Amount present/tablet	% of Assay
Etodolac	325mg	99.09
Paracetamol	400mg	98.42

Table 8: SYSTEM SUITABILITY PARAMETERS

System suitability parameters	Etodolac	Paracetamol
Tailing Factor	1.273	1.095
Theoretical plates	2094	4034
Resolution	-	5.423

CONCLUSION

The developed RP-HPLC method is simple, precise, accurate, selective and reproducible. The method has been found to be adequately in RT and robust can be used for simultaneous determination of Etodolac and Paracetamol in tablet formulation. The method was validated as per ICH guidelines.

ACKNOWLEDGEMENT

I Like to thankful to Pharma Tech Solution, Cherlapally, Hyderabad, India for providing the gift samples of Etodolac and Paracetamol. And also to the principal Dr.K.Rajeswar Dutt Smt.Sarojini Ramulamma College of Pharmacy, Mahabubnagar, Andhra pradesh, India and special thanks for Mrs. J.PRIYA madam and Ms.Ramathilagam madam as well as my friends who helped during the project work.

REFERENCES

- [1] Joel GH, Lee EL, Alfred GG. Goodman and Gilman's the pharmacological basis of Therapeutics. 11th ed. Mc Graw Hill, New York, U.S.A; 2001. p. 635.
- [2] <http://en.wikipedia.org/wiki/Etodolac>.
- [3] Indian Pharmacopoeia. Indian Pharmacopoeia Commission, Ghaziabad. 2010; 2: 1318,1859.
- [4] British Pharmacopoeia. Ph Euro monograph 1590. London, Medicines and Health care products Regulatory Agency (MHRA) 2003; 1: 752,1417.
- [5] United States Pharmacopoeia. The Pharmacopoeia of United States 27th ed. and The National Formulary 22nd ed. Asia edition 2004;770
- [6] Rang HP, Dale MM, Ritter JM, Flower RJ, Rang and Dale's pharmacology 6th Ed. Elsevier, London; 2007; 607.
- [7] Patidar R, Baghel US, Patela S, Singhal M, Patidara N, Englaa G, et al. Simultaneous estimation spectrophotometric estimation of Paracetamol and Etodolac in tablet dosage forms. Journal of Global Pharma Technology. 2009;1(1):62-6

- [8] Balan P, Carolin N, Lakshmi PM, Vanaja RM, Rajasekar S. Simultaneous estimation of Etodolac and Paracetamol by uv spectrophotometric method in tablet formulation. *J Pharm Res.* 2011;4(6):1663-5.
- [9] Gandhi SV, Chaube PH, Despande PB, Kulakarni VG. High Performance Thin Layer Chromatographic Analysis of Paracetamol and Etodolac in Spiked Human Plasma. *J Pharm Biomed Sci.* 2010;7 (13).
- [10] Gandhi SV, Chaube PH, Despande PB, Kulakarni VG. High Performance Thin Layer Chromatographic Analysis of Paracetamol and Etodolac in Combined Tablet dosage Form. *J.Chem.Pharm.Res.*,2012,4(3):1750-1755
- [11] Shaikh KA, Devkhile AB. Simultaneous determination of Aceclofenac, Paracetamol, and Chlorzoxazone by RP-HPLC in pharmaceutical dosage form. *J Chromatogram Sci.* 2008 ; 46: 649-652.
- [12] GraceSNL <http://www.sciencedirect.com/science/article/pii/S073170859400859-COR1>, Critchley JAJH. The estimation of paracetamol and its major metabolites in both plasma and urine by a single High-Performance Liquid Chromatography assay. *J Pharm Biomed Anal.* 1994;12:1563-72.
- [13] Erdal D, Abdil O, Halil A, Dumitru B. Chemometric approach to simultaneous chromatographic determination of Paracetamol and Chlorzoxazone in tablets and spiked human plasma. *J Liq Chromatograph Relat Technol.* 2006; 29: 1803-22.
- [14] Deepali G, Pandurang D. Simultaneous Estimation of Aceclofenac and Paracetamol in solid dosage form by RP-HPLC Method. *Int J of ChemTech Res.* 2010;2:942-6.
- [15] Momin MY, Yeole PG, Puranik MP, Wadher SJ. Reverse phase HPLC method for determination of Aceclofenac and Paracetamol in tablet dosage form. *Indian J Pharm sci.* 2006; 68: 387-9.
- [16] Vaijanath GD, Sweta BS, Gunaji SB, Manisha P, Vivek KJ. Simultaneous determination of Etodolac and Acetaminophen in tablet dosage form by RP-LC. *Chromatographia.* 2009; 69(9-10): 1019-23.
- [17] Vyas AJ, Aggarwal NA, Nagori BP, Patel JK, Jobanputra CR, Viramgama DS Simultaneous estimation of Nabumetone and Paracetamol by Vierodt's method in combined tablet dosage form. *International Journal of ChemTech Research.* 2010; 2(1): 543-47.
